{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-092414","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2023-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.895780+00:00","generated_at":"2026-06-17T05:52:58.927315+00:00","sec_items":["1.01","3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quince Therapeutics adopts one-year poison pill after unsolicited bid, share accumulation","bullets":["Rights plan effective immediately, expires April 5, 2024; dividend of one right per share on April 17, 2023.","Trigger at 10% beneficial ownership (15% for passive institutional); exercise price $6.00 per right.","Rights become exercisable if threshold crossed; holders (except triggering party) can buy shares at 2x market value.","Board may redeem rights for $0.001 each before trigger; company retaining financial advisor for strategic alternatives.","Plan adopted in response to unsolicited acquisition proposal and share accumulation by certain investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-092414","json":"https://secwatch.observer/filing/0001193125-23-092414.json","markdown":"https://secwatch.observer/filing/0001193125-23-092414.md","text":"https://secwatch.observer/filing/0001193125-23-092414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523092414/0001193125-23-092414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523092414/d487171d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:52:58.927315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d8307a2ae6beb93d68ea60293a28297facae1586","claim":"Quince Therapeutics, Inc.: Board adopted a limited duration stockholder rights plan, declaring a dividend of one preferred share purchase right per common share, effective immediately, expiring April 5, 2024 (effective 2023-04-05).","evidence_excerpt":"its Board of Directors (the “Board”) unanimously approved the adoption of a limited duration stockholder rights plan (the “Rights Plan”) and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince’s common stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523092414/0001193125-23-092414-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-04-05"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}